Cell Dissociation Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Cell Dissociation Market is segmented By Product Type (Enzymatic Dissociation Products (Collagenase, Trypsin, Papain, Elastase, DNase, Hyaluronidase, Others), Non-enzymatic Dissociation Products Instruments and Accessories), By Tissue (Connective Tissue, Epithelial Tissue, Others), By End-user (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031 

Cell Dissociation Market Report Overview

Cell Dissociation Market is estimated to grow at a CAGR of 10.5% during the forecast period 2024-2031

The cell dissociation process is also called Trypsinization. With the help of proteolytic enzymes, the adhering cell is separated from the surface or substrate. Cell dissociation cushions, which detach cell lines and tissues from containers' plastic or glass surfaces for increasing isolation efficacy with high cell practicality, have collagenolytic and proteolytic properties.

Cell Dissociation Market Summary

For More Insights about the Market Request Free Sample

Cell Dissociation Market Dynamics and Trends

The increasing R&D activities in biopharmaceutical companies are expected to drive market growth.

The biopharmaceutical industry's major firms are focusing on R&D in various therapeutic areas to bring novel pharmaceuticals to market. These businesses are doing so by investing substantially in clinical trials, efficacy studies, and toxicity studies, among other things. The vast majority of this research utilizes tissue dissociation products to isolate cells from primary tissues. For instance, The pharmaceutical sector spent $83 billion on research and development in 2019. Compared to the preceding decade, the number of new pharmaceuticals licensed for sale increased by 60% between 2010 and 2019, reaching a high of 59 new drugs approved in 2018.

Moreover, America's biopharmaceutical companies are committed to advancing personalized medicines. A recent industry survey revealed that 42% of new medicines in the pipeline could be personalized medicines. Additionally, Researchers and scientists are building on a huge body of knowledge that has gathered through time as they examine novel substances, illuminating illness pathways and providing insight into the best medication targets. Thus, the market is expected to drive in the forecast period.

Restraint:

The high cost of tissue and cell-based procedures, enzyme-free dissociation products are preferred over enzymatic dissociation products, ethical limits and concerns about the use of cell-based research and lack of infrastructure for cell-based research in developing regions are some of the factors due to which the market is expected to get hampered in the forecast period.

COVID-19 Impact on Cell Dissociation Market Growth

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic has provided crucial growth prospects. The amount of research and development to study and evaluate the virus that triggered the pandemic has doubled. Therefore, the market is likely to grow faster in developed nations with many research organizations. Countries in the Asia Pacific and other emerging regions, on the other hand, have increased their research on the new coronavirus.

In contrast, the COVID-19 pandemic has had a substantial impact on hospital resources worldwide. It has largely been accomplished by drastically lowering inpatient and outpatient services for various diseases and instituting infection prevention and control methods. The frequency of cancer screening and diagnostic treatments dropped dramatically, with the epidemic affecting countries worldwide. Thus, the market will undergo impetus growth during the forecast period.

Cell Dissociation Market Segment and Shares

The Enzymatic Dissociation Products segment is expected to hold the largest market share in the cell dissociation market

The enzymatic dissociation products segment is expected to dominate in 2020. Enzymatic dissociation is a method of disaggregating cell culture samples using particular proteins. The procedure uses enzymes such as trypsin and collagenase to break down tissue and release the target cells. The tissue type determines the enzyme used, and finding the optimum mix produces the best results. Moreover, enzymes are used in stem cell research and cell biology investigations for cell and tissue dissociation, primary cell separation, and single-cell harvesting. The employment of enzymes for cell dissociation is very common. Any dissociation procedure aims to get as many functionally viable dissociated cells as possible. The kind of tissue, age of the animal/human, dissociation media utilized, enzyme used, enzyme concentration, temperature, and genetic alterations all influence the outcome of any dissociation operation. As a result, numerous enzymes are used in research for various applications. Trypsin, collagenase, elastase, and hyaluronidase are among the most commonly employed enzymatic dissociation products in decreasing the frequency of use. Thus, the market segment is expected to boost in the forecast period from the above statements.

Cell Dissociation Market Geographical Analysis

North America region holds the largest market share in the global cell dissociation market

In 2020, North America accounted for the highest revenue share. Sustained expansion in the pharmaceutical and biotechnology sectors, rising cancer and other chronic illness incidences, and a strong trend of R&D investments in life sciences by industry and academia, acquisition, and collaboration by the key players in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. In contrast, in 2020, an estimated 1,806,590 new cancer cases were diagnosed in the United States, and 606,520 people died from the disease. The three most common cancers for women are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in 2020.

Moreover, in 2020, Thermo Fisher Scientific extended its strategic relationship with Symphogen (Denmark) to promote biopharmaceutical discovery and development. Thermo Fisher Scientific acquired QIAGEN N.V. (Germany) to extend its Specialty Diagnostics range. Therefore, it has increased the demand for cell dissociation products in the region. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements. 

Cell Dissociation Companies and Competitive Landscape

Major key players in the cell dissociation market are Merck KGaA, Thermo Fisher Scientific, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Miltenyi Biotec, PromoCell GmbH, AcceGen, Capricorn Scientific, Neuromics and Genlantis.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

­Product Portfolio:

Gibco: Gibco Cell Dissociation Buffer is a membrane-filtered, isotonic, and enzyme-free solution of salts, chelating agents, and cell-conditioning agents in calcium-free and magnesium-free phosphate-buffered saline (PBS).